-
公开(公告)号：KR1020080073419A
公开(公告)日：2008-08-11
申请号：KR1020070012002
申请日：2007-02-06
Applicant: (주)차바이오텍
IPC: A61K31/728 , A61K9/50
CPC classification number: A61K31/738 , A61K9/1682 , A61K2121/00
Abstract: A method for preparing a microbead of a hyaluronic acid derivative is provided to produce the microbead of the hyaluronic acid derivative efficiently through a high efficient reaction and a simple recovery process using a small amount of a crosslinking agent, the microbead showing excellent bio-compatibility, excellent swellability and excellent physical stability, thereby the microbead being usefully used as a filler, an implant, a drug delivery matrix, a cell carrier, a scaffold, and an agent for improving joint function. To prepare a microbead of a hyaluronic acid derivative, a hyaluronic acid or an alkaline aqueous solution of a salt thereof is crosslinked with an oil layer using 1,4-butandiol diglycidyl ether(BDDE) as a crosslinking agent with mixing. A microbead of hyaluronic acid derivatives for medical purpose is prepared by the method and is able to be sterilized at a temperature of 121 deg.C. Further, the oil is natural oil, synthesis oil or mineral oil, and has 10 to 500 cP of viscosity.
Abstract translation: 提供一种制备透明质酸衍生物的微珠的方法，通过高效反应和使用少量交联剂的简单回收方法有效地生产透明质酸衍生物的微珠，显示优异的生物相容性的微珠， 优异的溶胀性和优异的物理稳定性，从而微珠可用作填料，植入物，药物递送基质，细胞载体，支架和用于改善关节功能的药剂。 为了制备透明质酸衍生物的微珠，使用1,4-丁二醇二缩水甘油醚（BDDE）作为交联剂混合，用油层将透明质酸或其盐的碱性水溶液交联。 用于医疗目的的微珠透明质酸衍生物通过该方法制备，并且能够在121℃的温度下灭菌。 此外，油是天然油，合成油或矿物油，并且具有10至500cP的粘度。
-
公开(公告)号：KR1020100132878A
公开(公告)日：2010-12-20
申请号：KR1020090051688
申请日：2009-06-10
Applicant: (주)차바이오텍 , 가톨릭대학교 산학협력단
IPC: A61K9/06 , A61P41/00 , A61K31/728 , A61K31/336
CPC classification number: A61K31/728 , A61K9/06
Abstract: PURPOSE: An anti-adhesion agent containing hyaluronic acid epoxide derivative hydrogel and a method for manufacturing the same are provided to prevent adhesion between tissues without side effects. CONSTITUTION: An anti-adhesion agent contains hyaluronic acid epoxide derivative hydrogen. The particle size of the hydrogel is 100-300 um. The viscosity and crosslinking density of the hydrogel are 100,000 cP (0.02 Hz)-6,000,000 cP (0.02 Hz) and 0.2 mol%-100 mol%, respectively. The hydrogel is prepared by reacting hyaluronic acid and epoxide crosslinking agent in NaOH solution or crossliking 0.1-200 weight parts of crosslinking agent based on 100 weight parts of repeat unit of the hyaluronic acid.
Abstract translation: 目的：提供含有透明质酸环氧化物衍生物水凝胶的防粘连剂及其制造方法，以防止组织之间的粘连而无副作用。 构成：抗粘连剂含有透明质酸环氧化物衍生物氢。 水凝胶的粒径为100-300微米。 水凝胶的粘度和交联密度分别为100,000cP（0.02Hz）-6,000,000cP（0.02Hz）和0.2mol％-100mol％。 水凝胶是通过使透明质酸和环氧化物交联剂在NaOH溶液中反应制备的，或者以100重量份的透明质酸重复单元交联0.1-200重量份交联剂。
-
公开(公告)号：KR1020100089391A
公开(公告)日：2010-08-12
申请号：KR1020090008608
申请日：2009-02-03
Applicant: (주)차바이오텍
Abstract: PURPOSE: A novel transformation system in Sebekia benihana is provided to express homo or hetero protein or polypeptide and to transform physiologically active material. CONSTITUTION: A method for transforming Sebekia benihana strain comprises: a step of culturing Sebekia benihana for 3-7 days to form spore; a step of performing heat shock at 40-60 °C fkor 15-25 minutes and inducing germination of mycelium; a step of cooling at room temperature; a step of preparing transformed E.coli with an expression vector; a step of mixing the mycelium and E.coli and culturing for 16-18 hours; a step of selecting Sebekia benihana.
Abstract translation: 目的：提供Sebekia benihana中的新型转化系统，以表达同源或杂蛋白或多肽并转化生理活性物质。 构成：转化Sebekia benihana菌株的方法包括：培养Sebekia benihana 3-7天形成孢子的步骤; 在40-60°F，15〜25分钟内进行热休克并诱导菌丝体发芽的步骤; 在室温下冷却的步骤; 用表达载体制备转化的大肠杆菌的步骤; 将菌丝体与大肠杆菌混合并培养16-18小时的步骤; 选择Sebekia benihana的一个步骤。
-
Patent Agency Ranking
公开(公告)号：KR101180286B1
公开(公告)日：2012-09-14
申请号：KR1020090051688
申请日：2009-06-10
Applicant: (주)차바이오텍 , 가톨릭대학교 산학협력단
IPC: A61K9/06 , A61P41/00 , A61K31/728 , A61K31/336
Abstract: 본 발명은 히알루론산 에폭사이드 유도체 하이드로겔을 포함하는 유착방지제 및 이의 제조 방법에 관한 것이다. 보다 상세하게는, 본 발명은 수술 후 조직 간의 유착 방지 등의 용도로 사용되는 히알루론산 에폭사이드 유도체 하이드로겔을 포함하는 유착방지제 및 이의 제조 방법에 대한 것이다.
유착방지제-
5.发明公开
公开(公告)号：KR1020090012439A
公开(公告)日：2009-02-04
申请号：KR1020070076258
申请日：2007-07-30
Applicant: (주)차바이오텍 , 가톨릭대학교 산학협력단
IPC: A61K31/728 , A61P17/02
CPC classification number: A61K31/738 , A61K9/06 , A61K9/7007 , A61K2121/00
Abstract: A hyaluronic acid and a carboxy methyl cellulose composite derivative film is provided to have trachea reducing adhesion property, excellent biodegradation property and property absorbed by being completely disassembled after preventing adhesion phenomenon. An N-acylation urea pendant form and an auto-cross-linking form are mixed in hyaluronic acid and carboxy methyl cellulose composite derivative film. The N-acylation urea pendant form and an auto-cross-linking form are made by reacting crosslink activity agent and cross linkage activity supplement at hyaluronic acid and carboxy methyl cellulose complex film surface. The derivative film with the N-acylation urea pendant form is formed by using the crosslink activity agent 0.01 ~ 500 parts by weight and the cross linkage activity supplement 0.01 ~ 200 parts by weight based on compound of the carboxy methyl cellulose and hyaluronic acid 100 parts by weight. The derivative film with the auto-cross-linking form is formed by using the crosslink activity agent 0.01 ~ 500 parts by weight and the cross linkage activity supplement 40 ~ 1000 parts by weight.
Abstract translation: 提供透明质酸和羧甲基纤维素复合衍生物膜，以具有气管降低粘附性，优异的生物降解性能和性能在防止粘附现象后被完全分解吸收。 透明质酸和羧甲基纤维素复合衍生物膜混合N-酰化脲的侧链形式和自动交联形式。 通过在透明质酸和羧甲基纤维素复合膜表面上交联活性剂和交联活性补充剂反应制备N-酰化脲垂饰形式和自动交联形式。 通过使用0.01〜500重量份的交联活性剂和基于羧甲基纤维素和透明质酸化合物的交联活性补充0.01〜200重量份形成具有N-酰化脲侧链形式的衍生物膜100份 重量。 具有自交联形式的衍生物膜通过使用0.01〜500重量份的交联活性剂形成，交联活性为40〜1000重量份。
-
公开(公告)号：KR101075414B1
公开(公告)日：2011-10-24
申请号：KR1020090008608
申请日：2009-02-03
Applicant: (주)차바이오텍
Abstract: 본발명은동종또는이종의단백질또는폴리펩티드를발현하기위한희귀방선균인세베키아베니하나 ()에서의신규한형질전환시스템에관한것으로, 구체적으로접합 (conjugation) 을이용한형질전환방법및 상기방법으로형질전환된유용생리활성물질의생물전환능력이향상된형질전환균주에관한것이다.
-
公开(公告)号：KR1020100089396A
公开(公告)日：2010-08-12
申请号：KR1020090008618
申请日：2009-02-03
Applicant: (주)차바이오텍
Abstract: PURPOSE: A novel transformation system in Tolypocladiium niveum is provided to enhance cyclosporine A productivity and to industrially and medically use. CONSTITUTION: A method for preparing transformed Tolypocladium niveum comprises: a step of forming protoplast of Tolypocladium niveum; a step of preparing a recombinant vector in which foreign gene is introduced; a step of transforming by mixing PEG and the recombinant vector together with the protoplast; and a step of selecting Tolypocladium niveum using a selection marker. The transformed Tolypocladium niveum produces cyclosporine A of high concentrate.
Abstract translation: 目的：提供一种新的Tolypocladiium niveum的转化系统，以提高环孢菌素A的生产力和工业和医学应用。 构成：制备转化的土壤球菌的方法包括：形成铁皮假单胞菌原生质体的步骤; 制备引入外源基因的重组载体的步骤; 通过将PEG和重组载体与原生质体混合来转化的步骤; 以及使用选择标记选择Tolypocladium niveum的步骤。 转化的Tolypocladium niveum产生高浓度的环孢菌素A.
-
公开(公告)号：KR1020080062092A
公开(公告)日：2008-07-03
申请号：KR1020060137422
申请日：2006-12-29
Applicant: (주)차바이오텍
IPC: C08B37/08
CPC classification number: C08B37/0072 , A61K31/728
Abstract: A method for preparing hyaluronic acid derivatives is provided to produce three-dimensionally porous hyaluronic acid derivatives having characteristics usable as a cell delivery carrier through wet spinning. A method for preparing hyaluronic acid derivatives includes a step of producing the derivatives of hyaluronic acid or salts thereof having excellent biocompatibility and biodegradability usable as a cell delivery carrier of a cell treatment agent comprising stem cells through wet spinning. The biocompatible hyaluronic acid threads by wet spinning are produced by using a proper mixture solution of dimethylsulfoxide and distilled water as a solvent of a spinning solution for the hyaluronic acid or salt thereof, and using ethanol, dimethylformamide, or a mixture solution thereof as a solidifying solvent.
Abstract translation: 提供了一种制备透明质酸衍生物的方法，以制备具有通过湿纺丝可用作细胞递送载体的特征的三维多孔透明质酸衍生物。 制备透明质酸衍生物的方法包括制备具有优异生物相容性和生物降解性的透明质酸衍生物或其盐作为包含干细胞的细胞处理剂通过湿法纺丝的细胞递送载体的步骤。 通过使用二甲基亚砜和蒸馏水的合适的混合溶液作为透明质酸或其盐的纺丝溶液的溶剂，通过使用乙醇，二甲基甲酰胺或其混合溶液作为凝固剂，制备湿纺丝的生物相容性透明质酸线 溶剂。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.025 seconds)
